{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:08:40Z","timestamp":1760746120887,"version":"build-2065373602"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary aldosteronism (PA), the most prevalent curable secondary hypertension, and thyroid diseases (the second most common endocrine disorder) are increasingly linked, yet their mechanistic connections remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and methods<\/jats:title><jats:p>Four databases (PubMed, Embase, Web of Science, Cochrane Library) were searched for case-control studies. Random-effects meta-analysis and subgroup analyses for thyroid disease subtypes were performed. Sensitivity\/trial sequential analyses and Begg\u2019s test evaluated robustness\/publication bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our meta-analysis included five case-control studies, encompassing 1,368 patients with primary aldosteronism (PA) and 6,774 controls. While the overall prevalence of thyroid diseases was higher in PA patients (OR: 1.33, 95% CI:\u00a01.03-1.71, p=0.03), subgroup analysis revealed that this association was primarily driven by a significantly increased prevalence of thyroid nodules (OR: 1.85, 95%\u00a0CI: 1.23-2.80, p=0.003). No statistically significant associations were found between PA and other specific thyroid conditions, including hyperthyroidism, hypothyroidism, thyroiditis, or thyroid cancer (all p &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This first meta-analysis demonstrates a significant PA-thyroid disease association. The elevated overall risk of thyroid disease in PA patients appears to be largely attributable to the high burden of thyroid nodules. These findings suggest that patients with PA may benefit from targeted screening for thyroid nodules.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1614789","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:14:18Z","timestamp":1760674458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and risk of thyroid disease among adult primary aldosteronism patients: a systematic review, meta-analysis, and trial sequential analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wansong","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-023-01269-x","article-title":"Key to the treatment of primary aldosteronism in secondary hypertension: subtype diagnosis","volume":"25","author":"Zuo","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-020-00415-9","article-title":"Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension","volume":"27","author":"Rossi","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042111","article-title":"Atrial fibrillation and aortic ectasia as complications of primary aldosteronism: focus on pathophysiological aspects","volume":"23","author":"Bollati","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01614-3","article-title":"Hypothyroidism","volume":"404","author":"Taylor","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01025-4","article-title":"Thyroid nodules: diagnosis and management","volume":"20","author":"Grani","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00005-0","article-title":"Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis","volume":"11","author":"Wiersinga","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae087","article-title":"Associations between thyroid function, thyroid diseases, and primary aldosteronism","volume":"191","author":"Maiturouzi","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae653","article-title":"Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension","volume":"110","author":"Maciel","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00200-6","article-title":"Aberrant hormone receptors regulate a wide spectrum of endocrine tumors","volume":"12","author":"Lacroix","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e49913","DOI":"10.7759\/cureus.49913","article-title":"Thyroid hormone resistance syndrome: from molecular mechanisms to its potential contribution to hypertension","volume":"15","author":"Prakash","year":"2023","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5960563","article-title":"Aliskiren, fosinopril, and their outcome on renin-angiotensin-aldosterone system (RAAS) in rats with thyroid dysfunction","volume":"2019","author":"Farhadi","year":"2019","journal-title":"Int J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.901793","article-title":"Hypokalemic paralysis complicated by concurrent hyperthyroidism and hyperaldosternoism: A case report","volume":"18","author":"Hsiao","year":"2017","journal-title":"Am J Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.722912","article-title":"Vitamin D, thyroid hormones and cardiovascular risk: exploring the components of this novel disease triangle","volume":"12","author":"Vassalle","year":"2021","journal-title":"Front Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4158\/EP-2019-0374","article-title":"Renal function and plasma renin activity as potential factors causing hyperkalemia in patients with thyroid carcinoma undergoing thyroid hormone withdrawal for radioactive iodine therapy","volume":"26","author":"Niri","year":"2020","journal-title":"Endocr Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0880-2","article-title":"Association of primary aldosteronism with chronic thyroiditis","volume":"55","author":"Sabbadin","year":"2017","journal-title":"Endocrine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2011.144","article-title":"Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension","volume":"24","author":"Turchi","year":"2011","journal-title":"Am J Hypertens"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:22:2:155","article-title":"High prevalence of thyroid ultrasonographic abnormalities in primary aldosteronism","volume":"22","author":"Armanini","year":"2003","journal-title":"Endocrine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.20431\/2455-5983.0501001","article-title":"Thyroid \u0410bnormalities in primary aldosteronism","volume":"5","author":"Matrozova","year":"2019","journal-title":"ARC J Diabetes Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.08.015","article-title":"Cardiovascular risks and organ damage in secondary hypertension","volume":"48","author":"Cingolani","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3390\/biomedicines12112479","article-title":"Exploring the spectrum of comorbidities associated with primary aldosteronism: insights from a large real-world case-control study","volume":"12","author":"Krieg","year":"2024","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00991-4","article-title":"Actions of thyroid hormones and thyromimetics on the liver","volume":"22","author":"Sinha","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EJE-09-0410","article-title":"Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area","volume":"161","author":"Ayturk","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.3390\/ijms251910628","article-title":"Metabolic syndrome, thyroid dysfunction, and cardiovascular risk: the triptych of evil","volume":"25","author":"Pingitore","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13168","article-title":"The effect of eplerenone on the renin-angiotensin-aldosterone system of rats with thyroid dysfunction","volume":"71","author":"Dizaye","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1211991","article-title":"Regulation of the HGF-receptor c-met in the thyroid gland","volume":"106","author":"Schulte","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.4.4723","article-title":"Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia","volume":"83","author":"Thompson","year":"1998","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1614789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:14:19Z","timestamp":1760674459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1614789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":35,"alternative-id":["10.3389\/fendo.2025.1614789"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1614789","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1614789"}}